RWC 2024: An overview of real world geographic atrophy data
May 23rd 2024Retina World Congress
Durga Borkar, MD, MMCi, spoke with Modern Retina about the quality data (Qdata) gathered on geographic atrophy as well as the GATHER 1 and GATHER 2 data she presented at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.
RWC 2024: What if diabetic retinopathy patients are lost to follow-up?
May 22nd 2024Retina World Congress
J. Fernando Arevalo, MD, PhD, FACS, FASRS, spoke about a recent study looking at what happens to patients with diabetic retinopathy who are lost to follow-up. He presented this research at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.
ARVO 2024: Reduction in hard exudates with faricimab vs aflibercept in patients with DME
May 19th 2024ARVO
At this year's ARVO meeting, Roger Goldberg, MD, presented a paper on hard exudates and their resolution in patients with diabetic macular edema treated with either faricimab or 2 mg aflibercept.
ARVO 2024: Exploratory analysis of pivotal phase 3 trials, YOSEMITE and RHINE, for vabysmo in DME
May 18th 2024ARVO
At this year's ARVO meeting, Daniela Ferrara, MD, PhD, FASRS, presented a paper on predicting functional outcomes for different treatment durations of faricimab in diabetic macular edema.
RWC 2024: Week 52 safety and efficacy data from the US phase 1 trial of OTX-TKI
May 16th 2024Retina World Congress
Dilsher S. Dhoot, MD, shared details about the Week 52 safety and efficacy data from the US phase 1 clinical trial of sustained-release axitinib hydrogel implant (OTX-TKI) for neovascular age-related macular degeneration at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.
ARVO 2024: Feasibility and clinical efficacy of an OCT B-scan of interest tool
May 16th 2024ARVO
At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Niranchana Manivannan, PhD. She spoke about the poster presentation, "Feasibility and clinical efficacy of an OCT B-scan of interest tool."
ARVO 2024: Predicting 3-year myopia control efficacy from 1-year data
May 13th 2024ARVO
At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Noel Brennan, MScOptom, PhD. The clinical research fellow at Johnson and Johnson shared highlights from his presentation on myopia control and predictive modeling.